Cargando…
DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18–24 months old
BACKGROUND: The new combination of DTwP-HB-Hib vaccines has been developed in Indonesia following World Health Organization (WHO) recommendation and integrated into national immunization program. The aims of the study were to measure 1) antibody persistence 12–18 months after a primary series, 2) im...
Autores principales: | Gunardi, Hartono, Rusmil, Kusnandi, Fadlyana, Eddy, Soedjatmiko, Dhamayanti, Meita, Sekartini, Rini, Tarigan, Rodman, Satari, Hindra Irawan, Medise, Bernie Endyarni, Sari, Rini Mulia, Bachtiar, Novilia Sjafri, Kartasasmita, Cissy B., Hadinegoro, Sri Rezeki S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971417/ https://www.ncbi.nlm.nih.gov/pubmed/29804542 http://dx.doi.org/10.1186/s12887-018-1143-6 |
Ejemplares similares
-
The immunogenicity, safety, and consistency of an Indonesia combined DTP-HB-Hib vaccine in expanded program on immunization schedule
por: Rusmil, Kusnandi, et al.
Publicado: (2015) -
A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report
por: Medise, Bernie Endyarni, et al.
Publicado: (2020) -
Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine
por: Medise, Bernie Endyarni, et al.
Publicado: (2019) -
Correction: Dengue seroprevalence and force of primary infection in a representative population of urban dwelling Indonesian children
por: Prayitno, Ari, et al.
Publicado: (2018) -
Dengue seroprevalence and force of primary infection in a representative population of urban dwelling Indonesian children
por: Prayitno, Ari, et al.
Publicado: (2017)